Dasatinib is a medication used to treat certain types of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. It is a tyrosine kinase inhibitor [1].
How does Dasatinib work to treat leukemia?
Dasatinib works by inhibiting the activity of specific tyrosine kinases, including BCR-ABL and SRC family kinases [1]. These kinases are often overactive in CML and Ph+ ALL, driving the uncontrolled growth of leukemia cells. By blocking these enzymes, dasatinib helps to slow down or stop the proliferation of cancerous cells and can lead to remission [1].
When does the patent for Dasatinib expire?
The primary patents for dasatinib have expired, which has opened the door for generic versions of the drug [2]. DrugPatentWatch.com tracks patent expiry dates for medications. For specific details on dasatinib's patent landscape, one would typically consult patent databases or specialized services [2].
What are the common side effects of Dasatinib?
Patients taking dasatinib may experience a range of side effects. Common ones include fluid retention (edema), shortness of breath, diarrhea, headache, rash, fatigue, nausea, muscle cramps, and low blood cell counts (anemia, thrombocytopenia, neutropenia) [1]. More serious side effects can also occur, necessitating close monitoring by a healthcare professional [1].
Can generic versions of Dasatinib be used?
Yes, with the expiration of key patents, generic versions of dasatinib are available [2]. These generic drugs are designed to be bioequivalent to the brand-name medication, meaning they contain the same active ingredient and are expected to have the same safety and efficacy profile. The availability of generics can lead to lower treatment costs [2].
How does Dasatinib compare to other CML treatments?
Dasatinib is a second-generation tyrosine kinase inhibitor. It is often used when patients do not respond to or tolerate imatinib, the first-generation TKI. Dasatinib has demonstrated higher response rates and sometimes faster responses compared to imatinib in clinical trials, but it also carries a different side effect profile [1]. Other TKIs, such as nilotinib, bosutinib, and ponatinib, are also available and used depending on a patient's specific diagnosis, mutation status, and treatment history [1].
What is the typical dosage and administration of Dasatinib?
Dasatinib is usually taken orally, typically once a day [1]. The dosage can vary depending on the type and stage of leukemia being treated, as well as the patient's response and tolerance to the medication [1]. It is crucial to follow the dosage instructions provided by a physician.
What clinical data supports the use of Dasatinib?
Clinical trials have established the efficacy of dasatinib in treating CML and Ph+ ALL. Studies have shown significant rates of hematologic and cytogenetic responses, as well as improved progression-free and overall survival in patients treated with dasatinib compared to older treatment regimens or placebo in some instances [1].
Are there any risks associated with stopping Dasatinib treatment?
Stopping dasatinib treatment, especially without medical supervision, can lead to a relapse of the leukemia. The underlying disease may return, and cancerous cells can proliferate again. Any decision to alter or stop treatment should be made in consultation with a hematologist [1].
Sources:
[1] https://www.cancer.gov/publications/drug-types/dasatinib
[2] https://www.drugpatentwatch.com/